Hematologic Diseases

4
Pipeline Programs
9
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
Detection of microbial DNA in blood by SeptiFast TestPhase 4
MaaT Pharma
MaaT PharmaFrance - Lyon
1 program
1
MaaT033 capsulePhase 11 trial
Active Trials
NCT04150393CompletedEst. Dec 2021
Rallybio
RallybioNEW HAVEN, CT
1 program
1
RLYB116 for InjectionPhase 11 trial
Active Trials
NCT06797375Completed16Est. Feb 2026
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
Vincristine Sulfate LiposomePhase 11 trial
Active Trials
NCT04243434UnknownEst. Oct 2020
GS
Gilead SciencesFOSTER CITY, CA
2 programs
NewSpringForMe digital solutionN/A1 trial
NewSpringForMe digital solutionN/A
Active Trials
NCT06148610Unknown170Est. Dec 2024
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
NewSpringForMe digital solutionN/A
Pfizer
PfizerNEW YORK, NY
1 program
NewSpringForMe digital solutionN/A
Novartis
NovartisBASEL, Switzerland
1 program
NewSpringForMe digital solutionN/A
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
ex-vivo drug response assayN/A1 trial
Active Trials
NCT03488641Completed80Est. Aug 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RallybioRLYB116 for Injection
MaaT PharmaMaaT033 capsule
Acrotech BiopharmaVincristine Sulfate Liposome
Gilead SciencesNewSpringForMe digital solution
Heidelberg Pharmaex-vivo drug response assay

Clinical Trials (5)

Total enrollment: 266 patients across 5 trials

NCT06797375RallybioRLYB116 for Injection

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants

Start: Apr 2025Est. completion: Feb 202616 patients
Phase 1Completed
NCT04150393MaaT PharmaMaaT033 capsule

Safety and Tolerability Evaluation of MaaT033

Start: Oct 2020Est. completion: Dec 2021
Phase 1Completed
NCT04243434Acrotech BiopharmaVincristine Sulfate Liposome

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Start: Aug 2020Est. completion: Oct 2020
Phase 1Unknown
NCT06148610Gilead SciencesNewSpringForMe digital solution

Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support

Start: Sep 2022Est. completion: Dec 2024170 patients
N/AUnknown
NCT03488641Heidelberg Pharmaex-vivo drug response assay

Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer

Start: Apr 2018Est. completion: Aug 202180 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 companies competing in this space